Komori
Treasury Shares4577Daito Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Concerning the Acquisition of Treasury Shares and the Purchase of Treasury Shares Through an Off-Auction Purchase Transaction (ToSTNeT-3)

The Board of Directors resolved to acquire up to 500,000 common shares for a total amount of up to ¥625 million. The acquisition will be conducted through ToSTNeT-3 on 13 July 2026.

Worth reading
49Recurring
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
500000
Shares
Wording
Conditional
How definitive the wording is.

Resolution on acquisition limit

Resolved 10 July 2026Off-auction purchase (ToSTNeT-3)
Total acquisition price¥625,000,000 (maximum)
Maximum number of shares to be acquired500,000 shares (upper limit)The Company's common shares
1.7%Maximum number that can be acquired

The full horizontal line represents all issued shares, with marks at 10% intervals. The colored section represents the percentage stated in the resolution as the maximum proportion that may be repurchased under it.
This is a limit, and does not mean that the company will buy back all of it. The amount actually acquired will be shown in a later disclosure on the status of the acquisition of treasury shares.

Reason for acquisition

The Company will acquire treasury shares to strengthen shareholder returns and improve capital efficiency as part of the capital policy under its medium-term management plan.

Reference (number of shares stated in the document)
Current number of treasury shares16,718 shares (as of 30 June 2026). This excludes 94,340 of the Company's shares held as trust assets for the stock delivery trust for officers.
Total number of issued shares28,838,162 shares (as of 30 June 2026, excluding treasury shares)
Resolution on acquisition limit
ItemDetails
Class of shares to be acquiredThe Company's common shares
Maximum number of shares to be acquired500,000 shares (upper limit)
Percentage of total issued shares1.7%
Total acquisition price¥625,000,000 (maximum)
Method of acquisitionOff-auction purchase (ToSTNeT-3)
Reason for acquisitionThe Company will acquire treasury shares to strengthen shareholder returns and improve capital efficiency as part of the capital policy under its medium-term management plan.
Resolution date10 July 2026
Current number of treasury shares16,718 shares (as of 30 June 2026). This excludes 94,340 of the Company's shares held as trust assets for the stock delivery trust for officers.
Total number of issued shares28,838,162 shares (as of 30 June 2026, excluding treasury shares)
Items this document does not state (7)
Acquisition periodNumber of shares to be retiredPercentage of total issued shares before retirementScheduled retirement dateTotal number of issued shares after retirementChange in acquisition periodChange in acquisition limit

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To strengthen shareholder returns and improve capital efficiency as part of the capital policy under the medium-term management plan.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Acquisition of Treasury Shares and the Purchase of Treasury Shares Through an Off-Auction Purchase Transaction (ToSTNeT-3) | Daito Pharmaceutical Co.,Ltd. (4577) timely disclosure | Komori